Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

By R. Avery, D. Pieramici, M. Rabena, A. Castellarin, M. Nasir, Matthew J. Giust. Ophthalmology (Rochester, Minn.), 2006

1,113 citations recorded by the source corpus.

Subfields: Epidemiology, Ophthalmology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/8b1db0b43534d0bd6a7ab3d2ac30b566e6129939

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Ophthalmology

1. Don H. Anderson
2. L. V. Johnson
3. G. Hageman
4. K. Eng
5. P. Kertes

In Radiology, Nuclear Medicine and Imaging

1. L. V. Johnson
2. K. Eng
3. Don H. Anderson
4. G. Hageman
5. P. Kertes

Citations in the corpus

• Recent developments in optical coherence tomography for imaging the retina. (2007, background): “, 2006a) or in monitoring the effect of recently introduced antiangiogenic drugs (Rosenfeld et al., 2005; Michels et al., 2005; Avery et al., 2006).”
• DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (2006, neutral): “terminal domain (111-165) of vascular endothelial growth”
• Ranibizumab in neovascular age-related macular degeneration (2006, positive): “Its use in proliferative diabetic retinopathy (Avery 2006; Spaide and Fisher 2006), macular edema secondary to central retinal vein occlusion (Rosenfeld, Fung, et al 2005; Iturralde et al 2006), pseudophakic cystoid macular edema (Mason et al 2006), and neovascular glaucoma (Davidorf et al 2006)…”
• Age‐related macular degeneration—emerging pathogenetic and therapeutic concepts (2006, background): “It is important to note that Avastin has not yet undergone the toxicity studies and controlled trials that are required by the FDA for ocular application (58,59).”